149 related articles for article (PubMed ID: 12652114)
1. Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
Morita H; Suzuki G; Mishima T; Chaudhry PA; Anagnostopoulos PV; Tanhehco EJ; Sharov VG; Goldstein S; Sabbah HN
Cardiovasc Drugs Ther; 2002 Sep; 16(5):443-9. PubMed ID: 12652114
[TBL] [Abstract][Full Text] [Related]
2. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction.
Sabbah HN; Shimoyama H; Kono T; Gupta RC; Sharov VG; Scicli G; Levine TB; Goldstein S
Circulation; 1994 Jun; 89(6):2852-9. PubMed ID: 8205701
[TBL] [Abstract][Full Text] [Related]
4. Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure.
Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Tanhehco EJ; Goldstein S; Sabbah HN
Cardiovasc Drugs Ther; 2002 May; 16(3):209-14. PubMed ID: 12374898
[TBL] [Abstract][Full Text] [Related]
5. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
Rastogi S; Sharov VG; Mishra S; Gupta RC; Blackburn B; Belardinelli L; Stanley WC; Sabbah HN
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2149-55. PubMed ID: 18820026
[TBL] [Abstract][Full Text] [Related]
6. Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure.
Hole T; Frøland G; Gullestad L; Offstad J; Skjaerpe T
Echocardiography; 2004 Apr; 21(3):215-23. PubMed ID: 15053783
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Goldstein S; Sabbah HN
J Am Coll Cardiol; 2000 Jan; 35(1):222-9. PubMed ID: 10636284
[TBL] [Abstract][Full Text] [Related]
8. Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure.
Tanimura M; Sharov VG; Shimoyama H; Mishima T; Levine TB; Goldstein S; Sabbah HN
Am J Physiol; 1999 Apr; 276(4):H1385-92. PubMed ID: 10199866
[TBL] [Abstract][Full Text] [Related]
9. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
Morita H; Khanal S; Rastogi S; Suzuki G; Imai M; Todor A; Sharov VG; Goldstein S; O'Neill TP; Sabbah HN
Am J Physiol Heart Circ Physiol; 2006 Jun; 290(6):H2522-7. PubMed ID: 16428338
[TBL] [Abstract][Full Text] [Related]
10. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure.
Imai M; Rastogi S; Gupta RC; Mishra S; Sharov VG; Stanley WC; Mika Y; Rousso B; Burkhoff D; Ben-Haim S; Sabbah HN
J Am Coll Cardiol; 2007 May; 49(21):2120-8. PubMed ID: 17531662
[TBL] [Abstract][Full Text] [Related]
11. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure.
Groenning BA; Nilsson JC; Sondergaard L; Fritz-Hansen T; Larsson HB; Hildebrandt PR
J Am Coll Cardiol; 2000 Dec; 36(7):2072-80. PubMed ID: 11127443
[TBL] [Abstract][Full Text] [Related]
12. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
Suzuki G; Mishima T; Tanhehco EJ; Sharov VG; Todor A; Rostogi S; Gupta RC; Chaudhry PA; Anagnostopoulos PV; Nass O; Goldstein S; Sabbah HN
Br J Pharmacol; 2003 Jan; 138(2):301-9. PubMed ID: 12540520
[TBL] [Abstract][Full Text] [Related]
13. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).
Ghali JK; Piña IL; Gottlieb SS; Deedwania PC; Wikstrand JC;
Circulation; 2002 Apr; 105(13):1585-91. PubMed ID: 11927527
[TBL] [Abstract][Full Text] [Related]
14. Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.
Zacà V; Rastogi S; Mishra S; Wang M; Sharov VG; Gupta RC; Goldstein S; Sabbah HN
Cardiology; 2009; 112(4):294-302. PubMed ID: 18832825
[TBL] [Abstract][Full Text] [Related]
15. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
Hjalmarson A; Goldstein S; Fagerberg B; Wedel H; Waagstein F; Kjekshus J; Wikstrand J; El Allaf D; Vítovec J; Aldershvile J; Halinen M; Dietz R; Neuhaus KL; Jánosi A; Thorgeirsson G; Dunselman PH; Gullestad L; Kuch J; Herlitz J; Rickenbacher P; Ball S; Gottlieb S; Deedwania P
JAMA; 2000 Mar; 283(10):1295-302. PubMed ID: 10714728
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.
Di Lenarda A; Sabbadini G; Salvatore L; Sinagra G; Mestroni L; Pinamonti B; Gregori D; Ciani F; Muzzi A; Klugmann S; Camerini F
J Am Coll Cardiol; 1999 Jun; 33(7):1926-34. PubMed ID: 10362195
[TBL] [Abstract][Full Text] [Related]
17. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.
Colucci WS; Kolias TJ; Adams KF; Armstrong WF; Ghali JK; Gottlieb SS; Greenberg B; Klibaner MI; Kukin ML; Sugg JE;
Circulation; 2007 Jul; 116(1):49-56. PubMed ID: 17576868
[TBL] [Abstract][Full Text] [Related]
18. Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure.
Groenning BA; Nilsson JC; Hildebrandt PR; Kjaer A; Fritz-Hansen T; Larsson HB; Sondergaard L
Eur J Heart Fail; 2002 Oct; 4(5):635-46. PubMed ID: 12413508
[TBL] [Abstract][Full Text] [Related]
19. Ventricular remodeling: insights from pharmacologic interventions with angiotensin-converting enzyme inhibitors.
Goldstein S; Sharov VG; Cook JM; Sabbah HN
Mol Cell Biochem; 1995 Jun 7-21; 147(1-2):51-5. PubMed ID: 7494555
[TBL] [Abstract][Full Text] [Related]
20. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF).
Ghali JK; Wikstrand J; Van Veldhuisen DJ; Fagerberg B; Goldstein S; Hjalmarson A; Johansson P; Kjekshus J; Ohlsson L; Samuelsson O; Waagstein F; Wedel H;
J Card Fail; 2009 May; 15(4):310-8. PubMed ID: 19398079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
